The Leading Source for Pharmaceutical & Biopharmaceutical Manufacturing News
FREE Daily Email Newsletter
Oregon Senate Passes Bill on Vaccination Education
June 10, 2013 8:24 am | by LAUREN GAMBINO,Associated Press | News | CommentsA bill that is intended to persuade more Oregon parents to take their kids to doctors for shots and get over their mistrust of conventional medicine has taken a big step in the Legislature with passage by the state Senate. Oregon has the nation's highest rate of parents refusing vaccinations for their kindergartners for nonmedical reasons.
Cumberland Pharmaceuticals Reports FDA Approval For Updated Acetadote Labeling
June 10, 2013 8:21 am | News | CommentsCumberland Pharmaceuticals Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved updated labeling for Acetadote (acetylcysteine) Injection. The new labeling revises the product's indication and offers new dosing guidance for specific patient populations.
FDA Finds Fungus in Drugs from Tennessee Pharmacy
June 10, 2013 8:17 am | by MATTHEW PERRONE,AP Health Writer | News | CommentsThe Food and Drug Administration said in an online posting Friday that it identified the growths in two unopened vials of a steroid injection distributed by the Main Street Family Pharmacy, a compounding pharmacy in Newbern, Tenn. The agency said it is working with the Centers for Disease Control and Prevention to identify the exact species of fungus and bacteria.
Ex-Worker Seeks Home for Miles Memorabilia
June 10, 2013 8:14 am | by TIM VANDENACK,The Elkhart Truth | News | CommentsArden Stickel is worried. He's getting on in years and won't be around forever, so he's got to figure out what to do with all his Miles Laboratories bottles and pills. And promotional Frisbees. And company newsletters. And Speedy dolls, Speedy being the Alka-Seltzer pitchman of yesteryear.
Elan Rejects Royalty Bid, To Evaluate Other Offers
June 10, 2013 8:10 am | by The Associated Press | News | CommentsThe board of directors of the Irish drugmaker Elan Corp. PLC on Monday rejected an increased offer from Royalty Pharma and says it has received unsolicited interest from other parties it didn't name. Royalty's latest offer last week was for $13 per share plus up to $2.50 per share in payments based on performance milestones. That offer totaled about $7.76 billion not counting the milestone payments.
AstraZeneca to Acquire Pearl Therapeutics to Strengthen Respiratory Portfolio
June 10, 2013 8:07 am | News | CommentsAstraZeneca announced today that it has entered into a definitive agreement to acquire Pearl Therapeutics, a privately held company based in Redwood City, California, focused on the development of inhaled small-molecule therapeutics for respiratory disease.
Weight Loss Drug Belviq Gets Overdue US Launch
June 7, 2013 11:39 am | by MATTHEW PERRONE - AP Health Writer - Associated Press | News | CommentsArena Pharmaceuticals says its weight loss drug Belviq will be available to U.S. patients beginning next week, nearly a year after the drug was officially approved by federal regulators. The Food and Drug Administration approved Belviq last June for adults who are obese or who are overweight and...
Flat Surface pH/ORP Electrode
June 7, 2013 11:33 am | Product Releases | CommentsThe S8000 series modular electrode platform has been expanded with the addition of the S8075CD in-line pH electrode and S8075CD-ORP in-line oxidation reduction potential (ORP) electrode.
Royalty Pharma Increases Offer to Acquire Elan
June 7, 2013 8:37 am | News | CommentsRoyalty Pharma today announced, pursuant to Rule 2.5 of the Irish Takeover Rules, a firm intention to further increase its offer for Elan to $13.00 per share in cash plus a contingent value right worth up to $2.50 per share. The CVR, based on feedback from Elan Shareholders, enables participation in the future upside of Tysabri including approval in secondary progressive multiple sclerosis and the achievement of certain sales milestones.
FDA: More Study Needed on Life-Saving Baby Drug
June 7, 2013 8:30 am | Videos | CommentsDr. Mark Puder of Boston Children’s Hospital developed a treatment with a drug made with fish oil called Omegaven that he’s been using to help reverse fatal liver disease in infants. Despite the drug’s effectiveness, it has yet to be approved by the FDA. Puder says the FDA has told him they want the usual rigorous controlled study where half the patients get the experimental drug and the other does not.
Actavis Confirms Generic Diprivan Patent Challenge
June 7, 2013 8:12 am | News | CommentsActavis, Inc. today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Propofol Injection 10mg/mL. Actavis' ANDA product is a generic version of Fresenius Kabi's Diprivan, which is an intravenously administered sedative and anesthetic.
Judge's Ruling Challenges US Transplant System
June 7, 2013 8:06 am | by LAURAN NEERGAARD,AP Medical Writer | News | CommentsIt's a life or death matter: Who gets the next scarce donated organ? In an unprecedented challenge to the nation's transplant system, a federal judge has allowed one dying child — and a day later another — to essentially jump the line in rulings that could have ramifications for thousands of people awaiting new organs.
Q & A on Court Ruling Affecting Morning-After Pill
June 7, 2013 8:02 am | by LINDSEY TANNER,AP Medical Writer | News | CommentsDon't expect to see morning-after pills for all ages on drugstore shelves anytime soon. A federal appeals court decision allowing girls of any age to buy emergency contraception without a prescription won't immediately change access. Labels first need to be revised to remove age restrictions, and the government could file another appeal to block moving the products from behind pharmacy counters.
MLB Asks for FedEx, Phone Records in Drug Lawsuit
June 7, 2013 7:54 am | by RONALD BLUM,AP Sports Writer | News | CommentsMajor League Baseball's lawyers issued subpoenas to Federal Express, AT&T Mobility and T-Mobile USA in an attempt to gain records for its investigation of players suspected of using performance-enhancing drugs. The subpoenas were issued May 23, according to a civil case file in Florida's Circuit Court for Miami-Dade County, where MLB sued Biogenesis of America, anti-aging clinic head Anthony Bosch and five others in March.
FDA Panel Wants Changes to Avandia Safety Measures
June 6, 2013 5:44 pm | by MATTHEW PERRONE - AP Health Writer - Associated Press | News | CommentsFederal health experts are recommending changes to safety restrictions on former blockbuster diabetes pill Avandia, in light of a new analysis suggesting that the drug may not increase the risk of heart attack as previously believed. A majority of Food and Drug Administration advisers voted...
